XML 47 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
COMMON STOCK, PREFERRED STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Tables)
12 Months Ended
Dec. 31, 2017
Schedule of Stock Grants Activity
The following tables present a summary of the status of the grants to employees, officers and directors as of December 31, 2017, 2016 and 2015:
 
   
Number
   
Weighted average exercise price (US$)
 
Balance outstanding as of December 31,2014
   
450,847
     
5.85
 
Exercised during 2015
   
(19,769
)
   
1.82
 
Forfeited during 2015
   
(17,605
)
   
6.01
 
Balance outstanding as of December 31,2015
   
413,473
     
6.04
 
Balance exercisable as of December 31,2015
   
293,736
     
5.95
 
Granted during 2016
   
149,330
     
4.53
 
Balance outstanding as of December 31,2016
   
562,803
     
5.64
 
Balance exercisable as of December 31,2016
   
334,735
     
5.81
 
Granted during 2017
   
4,740,318
     
5.22
 
Forfeited during 2017
   
(66,154
)
   
3.93
 
Balance outstanding as of December 31,2017
   
5,236,967
     
5.28
 
Balance exercisable of December 31,2017
   
2,428,716
     
5.28
 
Schedule of Stock Grants, by Exercise Price Range
The following tables summarize information about options outstanding at December 31, 2017:
 
Exercise
price (US$)
   
Outstanding at December 31, 2017
   
Weighted average remaining contractual life (years)
   
Exercise
price (US$)
   
Exercisable at December 31, 2017
   
Weighted average remaining contractual life (years)
 
 
6.25
     
351,712
     
4.19
     
6.25
     
351,712
     
4.19
 
 
6.02
     
4,273
     
0.03
     
6.02
     
4,273
     
0.03
 
 
7.00
     
22,000
     
6.50
     
7.00
     
22,000
     
6.50
 
 
4.75
     
12,000
     
8.01
     
4.75
     
12,000
     
8.01
 
 
4.50
     
79,998
     
8.21
     
4.50
     
79,998
     
8.21
 
 
4.50
     
26,666
     
8.88
     
4.50
     
22,793
     
8.88
 
 
4.50
     
1,673,996
     
9.21
     
4.50
     
1,231,016
     
9.21
 
 
5.41
     
559,414
     
9.21
     
5.41
     
0
     
0
 
 
7.75
     
844,130
     
9.21
     
7.75
     
0
     
0
 
 
4.50
     
661,875
     
9.26
     
4.50
     
304,615
     
9.26
 
 
7.75
     
50,000
     
9.26
     
7.75
     
16,667
     
9.26
 
 
4.50
     
74,470
     
9.41
     
4.50
     
65,709
     
9.41
 
 
4.50
     
290,585
     
9.48
     
4.50
     
140,660
     
9.48
 
 
4.50
     
585,848
     
9.71
     
4.50
     
177,273
     
9.71
 
         
5,236,967
                     
2,428,716
         
Schedule of Assumptions Used to Value Options
The fair value of options granted to employees was estimated at the dates of grant using the Black-Scholes option pricing model.  The following are the data and assumptions used:
 
   
2017
   
2016
 
Dividend yield (%)
   
0
     
0
 
Expected volatility (%) (*)
   
56.59
     
62.16
 
Risk free interest rate (%)
   
0.92
     
1.08
 
Expected term of options (years)
   
5-10.5
     
6
 
Exercise price (US dollars)
   
4.50 - 7.75
     
4.50, 4.75
 
Stock price (US dollars) (**)
   
2.38
     
2.38
 
Fair value (US dollars)
   
0.58-1.28
     
1.01, 098
 
 
   (*)
Due to the low trading volume of the Company’s Common Stock, the expected volatility was based on a sample of 254 companies operating in the Healthcare Products industry.
 
   (**)
The Common Stock price, per share for the year ended December 31, 2017 and 2016 reflects the Company’s management’s estimation of the fair value per share of Common Stock. In reaching its estimation for December 31, 2017, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the 2016 Offering. In reaching its estimation for December 31, 2017, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series C Units.
Series C Preferred Stock [Member]  
Schedule of Fair Value Assumptions
As of December 31, 2017, and 2016, The key inputs used in the fair value calculations of the Series C preferred warrant that were affected by the down-round protection were as follows:

   
December 31,
2017
   
December 31,
2016
 
Dividend yield (%)
   
-
     
-
 
Expected volatility (%)
   
56.59
     
56.59
 
Risk free interest rate (%)
   
1.31
     
0.92
 
Expected term of options (years)
   
3.27 - 4.58
     
4.27 - 4.92
 
Exercise price (US dollars)
   
4.50, 7.75
     
4.50, 7.75
 
Share price (US dollars)
   
2.45
     
2.38
 
Fair value (US dollars)
   
0.29 - 0.76
     
0.39 – 0.75
 
Series D Preferred Stock [Member]  
Schedule of Fair Value Assumptions
As of December 31, 2017, the key inputs used in the fair value calculations of the Series D preferred warrant that were affected by the down-round protection were as follows:

   
December 31,
2017
 
Dividend yield (%)
   
-
 
Expected volatility (%)
   
56.59
 
Risk free interest rate (%)
   
1.31
 
Expected term of options (years)
   
4.92
 
Exercise price (US dollars)
   
4.50, 5.75, 7.75
 
Share price (US dollars)
   
2.45
 
Fair value (US dollars)
   
0.81, 0.66, 0.5
 
Derivative Warrant Liability [Member]  
Schedule of Changes in Fair Value of Level 3 Liability
The changes in the fair value of the Level 3 liability are as follows (in US dollars):

   
Warrants with Down-Round Protection
 
   
December 31,
 
   
2017
   
2016
 
             
Balance, Beginning of the year
   
681,970
     
321,695
 
Warrants issued as consideration for placement services
   
353,721
     
308,239
 
Stock based compensation to financial advisor
   
32,880
     
-
 
Amount classified out of stockholders’ deficit and presented as Warrants with Down-Round Protection
   
-
     
341,662
 
Change in fair value of Warrants with Down-Round Protection
   
(300,322
)
   
(289,626
)
Balance, End of year
   
768,249
     
681,970
 
Schedule of Fair Value Assumptions

The key inputs used in the fair value calculations were as follows:

   
December 31,
2017
   
December 31,
2016
 
Dividend yield (%)
   
-
     
-
 
Expected volatility (%) (*)
   
56.59
     
56.59
 
Risk free interest rate (%)
   
1.31
     
0.92
 
Expected term of options (years)
   
0.2 - 4.92
     
1.20 - 4.92
 
Exercise price (US dollars)
   
4.50 – 7.75
     
4.50 - 7.75
 
Share price (US dollars) (**)
   
2.45
     
2.38
 
Fair value (US dollars) (***)
   
0.002 - 0.81
     
0.16 – 0.75
 

(*)
Due to the low trading volume of the Company’s Common Stock, the expected volatility was based on a sample of 254 companies operating in the Healthcare Products industry.
 
(**)
The Common Stock price, per share reflects the Company’s management’s estimation of the fair value per share of Common Stock as of December 31, 2017, and 2016. In reaching its estimation for such periods, management considered, among other things, a valuation prepared by a third-party valuation firm following the issuance of the Series D Units at December 31, 2017, as applicable to each reporting period.
 
 (***)  The below chart reflects the Fair Value for each of the Warrants with down-round Protection that were outstanding as of December 31, 2017 in US dollars.
 
   
Investors
   
AGI - Series A
   
AGI - Series B
   
AGI - Series C
   
AGI - Series D
 
Total quantity
   
126,935
     
364,071
     
566,897
     
844,605
     
37,777
 
Exercise price
   
4.5
     
4.5
     
4.5, 7.75
     
4.5, 7.75
     
4.5 5.75, 7.75
 
Fair value
   
0.31
     
0.12
     
0.12 – 0.34
     
0.29 – 0.76
     
0.5 – 0.81
 
 
Warrant [Member]  
Schedule of Fair Value Assumptions
As of December 31, 2017 and 2016, The key inputs used in the fair value calculations of the Series A preferred warrant that were affected by the down-round protection  were as follows:

   
December 31, 2017
   
December 31, 2016
 
   
Investors
   
Placement agent
   
Investors
   
Placement agent
 
Dividend yield (%)
   
0
     
0
     
0
     
0
 
Expected volatility (%)
   
56.69
     
56.69
     
56.69
     
56.69
 
Risk free interest rate (%)
   
1.31
     
1.31
     
0.92
     
0.92
 
Expected term of options (years)
   
0.2
     
2
     
1.2
     
3
 
Exercise price US dollars
   
4.5
     
4.5
     
4.5
     
4.5
 
Share price (US dollars)
   
2.45
     
2.45
     
2.38
     
2.38
 
Fair value (US dollars)
   
0.002
     
0.311
     
0.159
     
0.481